Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
PC3 cell line: 100 g
NCT03600480), in which 96 participants with a BMI of 27.039.9 kg/m were randomised 3:1 to once-weekly subcutaneous cagrilintide (0.16, 0.30, 0.60, 1.2, 2.4 or 4.5 mg) or matched placebo, each in combination with once-weekly semaglutide 2.4 mg , across six sequential overlapping cohorts
Patients may also consult the FDA drug shortage database to review the current availability status for semaglutide
In a study of 1,961 non-diabetic, obese or overweight adults with weight-related medical problems, 30% of participants prescribed Wegovy lost 20% or more weight vs
US$ 27.76
US$ 29.24
US$ 23.02
US$ 23.70
